BLUEPRINT MEDICINES CORP's ticker is BPMC and the CUSIP is 09627Y109. A total of 126 filers reported holding BLUEPRINT MEDICINES CORP in Q2 2017. The put-call ratio across all filers is 1.51 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2020 | $19,469,000 | +95.9% | 249,598 | +46.9% | 17.31% | +9.4% |
| Q1 2020 | $9,936,000 | -75.8% | 169,900 | -69.6% | 15.82% | +0.8% |
| Q3 2019 | $41,098,000 | -6.8% | 559,381 | +19.6% | 15.69% | +8.5% |
| Q2 2019 | $44,116,000 | +17.8% | 467,682 | 0.0% | 14.47% | +48.5% |
| Q1 2019 | $37,438,000 | +48.5% | 467,682 | 0.0% | 9.74% | +17.7% |
| Q4 2018 | $25,213,000 | +61.5% | 467,682 | +133.8% | 8.28% | +140.4% |
| Q3 2018 | $15,612,000 | -1.6% | 200,000 | -20.0% | 3.44% | +0.8% |
| Q2 2018 | $15,870,000 | -56.7% | 250,000 | -37.5% | 3.42% | -57.2% |
| Q1 2018 | $36,680,000 | +21.6% | 400,000 | 0.0% | 7.99% | -5.6% |
| Q4 2017 | $30,164,000 | -7.4% | 400,000 | -14.5% | 8.46% | -5.7% |
| Q3 2017 | $32,583,000 | +39.8% | 467,682 | +1.7% | 8.98% | +17.9% |
| Q2 2017 | $23,308,000 | +123.8% | 460,000 | +76.7% | 7.61% | +90.5% |
| Q1 2017 | $10,413,000 | +23.7% | 260,400 | -13.2% | 4.00% | +9.3% |
| Q4 2016 | $8,415,000 | – | 300,000 | – | 3.66% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aquilo Capital Management, LLC | 423,012 | $41,129,000 | 7.43% |
| Eagle Health Investments LP | 133,163 | $12,947,000 | 5.08% |
| DAFNA Capital Management LLC | 207,911 | $20,215,000 | 4.80% |
| Casdin Capital, LLC | 1,550,000 | $150,707,000 | 4.49% |
| SIB LLC | 65,151 | $6,335,000 | 3.72% |
| CADIAN CAPITAL MANAGEMENT, LP | 913,702 | $88,839,000 | 3.29% |
| Integral Health Asset Management, LLC | 117,500 | $11,425,000 | 3.26% |
| Rock Springs Capital Management LP | 746,732 | $72,605,000 | 1.58% |
| Avidity Partners Management LP | 546,000 | $53,088,000 | 1.47% |
| Zebra Capital Management LLC | 12,698 | $1,235,000 | 1.36% |